Ameriprise Financial Inc. Has $2.64 Million Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Ameriprise Financial Inc. boosted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 21.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 47,685 shares of the company's stock after purchasing an additional 8,336 shares during the period. Ameriprise Financial Inc. owned 0.12% of Tarsus Pharmaceuticals worth $2,640,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Summit Investment Advisors Inc. lifted its holdings in Tarsus Pharmaceuticals by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after purchasing an additional 244 shares during the last quarter. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter worth approximately $25,000. Bank of New York Mellon Corp lifted its holdings in Tarsus Pharmaceuticals by 0.5% during the 4th quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after purchasing an additional 498 shares during the last quarter. Swiss National Bank lifted its holdings in Tarsus Pharmaceuticals by 1.2% during the 4th quarter. Swiss National Bank now owns 52,333 shares of the company's stock worth $2,898,000 after purchasing an additional 600 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Tarsus Pharmaceuticals by 10.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock worth $449,000 after purchasing an additional 789 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Guggenheim raised their price objective on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Barclays lowered their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Jefferies Financial Group raised their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Oppenheimer assumed coverage on Tarsus Pharmaceuticals in a research note on Monday. They set an "outperform" rating and a $75.00 price objective on the stock. Finally, Wall Street Zen lowered Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Tarsus Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $66.67.

Insider Activity

In related news, General Counsel Bryan Wahl sold 3,341 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total transaction of $154,654.89. Following the sale, the general counsel now owns 58,057 shares in the company, valued at $2,687,458.53. The trade was a 5.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Bobak R. Azamian sold 7,131 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $330,093.99. Following the sale, the chief executive officer now owns 70,720 shares in the company, valued at $3,273,628.80. This represents a 9.16% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,542 shares of company stock worth $1,581,173. Insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Price Performance

Shares of TARS traded up $0.90 during midday trading on Monday, hitting $43.85. The company's stock had a trading volume of 624,727 shares, compared to its average volume of 702,013. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The company's fifty day simple moving average is $46.79 and its two-hundred day simple moving average is $48.95. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -11.51 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. As a group, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.